Lipid-Nanoparticle Delivery Patents: Who Leads, Where the Gaps Are 2026
- 26.1% of all 22,375 records sit with just five assignees, so most of the field is still a long tail of single- and few-filing entrants.
- Filings grew 11% from 2021 to 2024 (2,187 to 2,420), with a 2022 peak of 3,167 — the field is still active, not cooling, once the lag in recent-year publication is accounted for.
- A61K and C12N dominate the IPC mix at 68.5% and 47.6% of records respectively, leaving formulation-adjacent classes like G01N testing methods comparatively open.
Filing growth compares 2021 (2,187 records) with 2024 (2,420) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 22,375 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape draws on 22,375 published records spanning 2015 to the 2026 cut-off, indexed across title, abstract, claims and description for lipid nanoparticle delivery combined with formulation and material-property terms such as surface layer, particle morphology and dosage form. The scope pulls in both core LNP composition work and the surrounding drug-formulation art that determines whether a delivery system is actually manufacturable at scale.
Filing here tracks the mRNA therapeutics wave closely: the field's peak filing year so far is 2022, and receiving-office data shows the United States, WIPO/PCT and Europe as the three heaviest jurisdictions, with Australia, Canada and Israel forming a second tier. Because publication lags filing by roughly 18 months, the most recent one to two years in any trend chart will understate real filing activity.
Filing trend and technology composition
Two views of the same 22,375-record dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing trend, 2017-2026
Filings rose from 953 in 2017 to a peak of 3,167 in 2022, then eased to 202 in the still-incomplete 2026 count. The reliable comparison is 2021 to 2024 — complete years both — where volume grew from 2,187 to 2,420, an 11% increase. Treat 2025 and 2026 figures as provisional rather than a sign of decline.
IPC subclass composition
A61K (medicinal preparations) appears on 68.5% of records and C12N (microorganisms and genetic engineering) on 47.6%, confirming that most filings are anchored in formulation and nucleic-acid delivery rather than pure materials science. Smaller subclasses such as G01N (material analysis and testing) at 3.0% and C07C (acyclic and carbocyclic compounds) at 5.3% show far less claim density, which is where narrower, more specific filings still have room.
Shares are the percentage of the 22,375 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Lipid-Nanoparticle Delivery Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about lipid-nanoparticle delivery patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this landscape
WO2026006906A1 — Lipid nanoparticle delivery systems with enhanced stability
A lipid nanoparticle delivery system comprising a cargo molecule and a lipid nanoparticle encapsulating that cargo, where the nanoparticle includes ionizable lipids, helper lipids, sterol, and acid-containing lipids that are crosslinked, together with methods of use.Filed by Ebovir Biotechnology; published 2026-01-08 — illustrates how stability claims are now being built around crosslinked lipid chemistry rather than composition alone.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2012170930A1 | Lipid nanoparticle compositions and methods for mRNA delivery | 865 |
| 2 | WO2012170889A1 | Cleavable lipids | 830 |
| 3 | WO2015095340A1 | Lipids and lipid compositions for the delivery of active agents | 829 |
| 4 | US20120301498A1 | Controlled release of immunosuppressants from synthetic nanocarriers | 758 |
| 5 | WO2013151666A2 | Modified polynucleotides for the production of biologics and proteins associated with human disease | 748 |
| 6 | WO2011068810A1 | Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases | 739 |
| 7 | WO2017049245A2 | Compounds and compositions for intracellular delivery of therapeutic agents | 734 |
| 8 | WO2013052523A1 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | 689 |
| 9 | WO2013090648A1 | Modified nucleoside, nucleotide, and nucleic acid compositions | 688 |
| 10 | WO2017173054A1 | Lipid nanoparticle formulations for crispr/CAS components | 680 |
Citation counts favour older, foundational filings inside this searched corpus — read them as a signal of influence on later art, not as a ranking of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three read-throughs from the concentration, trend and citation figures above.
The core is claimed, the edges are not
The leader alone accounts for 2,308 records, and the top ten together hold 35.3% of all records in scope. That still leaves roughly two-thirds of the landscape spread across a long tail, which is where formulation-specific and manufacturing-process claims tend to sit unopposed.
Growth is real, not an artefact of partial years
Comparing two complete filing years — 2021 and 2024 — shows genuine growth despite year-over-year declines reported at several leading assignees in the most recent, still-incomplete year. That gap between aggregate growth and individual-assignee slowdown suggests new entrants are filling in behind the early movers.
Delivery chemistry and genetic payload dominate the claim set
Medicinal-preparation and genetic-engineering classes cover the bulk of the corpus, while material-testing and small-molecule carbocyclic classes sit under 6% each. That imbalance points to formulation and payload-delivery mechanics as the crowded ground, and characterisation methods as comparatively open.
A small cluster of institutions files jointly, repeatedly
The strongest co-filing relationships link a handful of research institutions together across multiple records, well above the next tier of pairings. That pattern typically reflects sponsored academic research feeding into licensed commercial filings rather than open collaboration across the field.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lipid-nanoparticle delivery patent landscape, with the prior art for and against each one.
Who is filing, and where the room to move sits
The ranked leaders are almost all names built around mRNA therapeutics and gene-editing platforms, with research universities filing alongside the commercial developers they license to.
One filer sits well ahead of the field
The top assignee's record count is more than four and a half times the fifth-place figure of 497, a gap wide enough that direct head-on filing against its core composition claims is unlikely to succeed without a materially different chemistry.
The drop-off past the leader is steep but not flat
Places two through ten still separate meaningfully from one another, meaning mid-tier assignees have carved distinct claim territory rather than clustering at the same volume. New entrants competing in this tier need to target a specific mechanism, not the category as a whole.
Leading filers have slowed sharply in the most recent year
Every one of the top academic and commercial filers shows a steep year-over-year drop in the latest count, consistent with publication lag rather than an actual pullback from the field. Do not read this as leaders exiting; read it as the newest filings not yet surfacing in the data.
| Assignee | Recent year | YoY |
|---|---|---|
| Alnylam Pharmaceuticals | 10 | -66% |
| The Trustees of the University of Pennsylvania | 9 | -82% |
| ModernaTX, Inc. | 7 | -85% |
| Board of Regents, The University of Texas System | 7 | -81% |
| Massachusetts Institute of Technology | 4 | -89% |
| The Broad Institute, Inc. | 4 | -80% |
| CRISPR Therapeutics AG | 2 | -83% |
| Translate Bio, Inc. | 1 | -94% |
Using this landscape in practice
The figures above answer where the field stands; what to do with them depends on where a team sits in the filing landscape.
For R&D teams scoping new formulation work
Check the IPC composition before committing lab time to a mechanism that already sits inside the dense A61K/C12N cluster — the return on a materially new lipid chemistry or characterisation method is higher than an incremental variant of existing composition claims.
Explore the technology map in EurekaFor IP counsel assessing freedom to operate
The concentration figures show where a small number of assignees hold defensible ground; clearing a path around the leader's core composition claims is a different exercise from clearing around the long tail.
Run a freedom-to-operate search in EurekaFor competitive intelligence tracking momentum
Year-over-year moves at individual assignees need to be read against the 18-month publication lag before concluding anyone has slowed down; the aggregate 2021-2024 growth figure is the more reliable signal.
Track assignee activity in EurekaCommon questions on LNP delivery patents
One assignee leads the ranked field with 2,308 records, well ahead of the fifth-place holder at 497 and tenth place at 336. The top five assignees combined hold 26.1% of all 22,375 records in scope, and the top ten hold 35.3%. That leaves close to two-thirds of the landscape distributed across a long tail of smaller filers, including several research universities that file jointly with the commercial leaders they license technology to.
Yes, based on the two most reliable complete years available: filings rose from 2,187 in 2021 to 2,420 in 2024, an 11% increase. The field's peak filing year so far is 2022 at 3,167. Figures for 2025 and 2026 look lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual slowdown, so those years should not be read as a decline.
Medicinal preparations (IPC class A61K) appear on 68.5% of the 22,375 records, and microorganisms and genetic engineering (C12N) appear on 47.6%, making formulation and nucleic-acid payload delivery the two most heavily claimed areas. Therapeutic activity (A61P) and peptides and proteins (C07K) follow at meaningfully lower shares. Because a single record can carry multiple IPC codes, these percentages overlap and do not sum to 100%.
The IPC composition data points to material-characterisation and structural areas as comparatively open: subclasses like G01N (material analysis and testing) sit at only 3.0% of records and C07C (acyclic and carbocyclic compounds) at 5.3%, far below the dominant A61K and C12N clusters. Specific technical branches worth examining include crosslinked acid-lipid stabilisation chemistry, particle-morphology characterisation methods, and surface-layer surfactant formulations, none of which show the filing density of core composition claims.
WO2026006906A1, filed by Ebovir Biotechnology and published in January 2026, claims a lipid nanoparticle delivery system built around ionizable lipids, helper lipids, sterol, and acid-containing lipids that are crosslinked, along with methods of use. The crosslinking of the acid-containing lipid component is the distinguishing feature over earlier composition-only claims. Anyone designing a competing stability mechanism should check whether their approach relies on crosslinking chemistry in the same lipid class, since that is the narrower technical hook this filing stakes out.
Research Lipid-Nanoparticle Delivery Patent Landscape in depth with Eureka
Go past this page: query the whole lipid-nanoparticle delivery patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.